重组免疫毒素EGF-TCSredlk治疗实体肿瘤实验研究

目的：使用EGF-TCSredlk重组蛋白对裸鼠的肿瘤模型进行体内抑瘤实验,观察其抗肿瘤效果。方法：分别给裸鼠皮下接种人肝癌BEL-7402细胞,接种后第6天,尾静脉注射100、50和25μg/kg EGF-TCSredlk进行治疗,设空白对照组,停药后第2天处死小鼠,称量瘤重,计算抑瘤率;肿瘤组织做免疫组织化学实验,从而研究其抑制肿瘤生长的途径。结果：高、中、低剂量组的抑制率分别为75.5%、54.5%和35.4%。对治疗结束后各组平均瘤重进行统计学分析,结果有显著性差异（Welch=82.617,P=0.000）;免疫组化结果显示EGF-TCSredlk可以明显的抑制肿瘤血管的形成,高剂量组肿瘤组织未有可见血管,中低剂量组肿瘤组织血管明显少于模型组,其抑制肿瘤生长的途径可能是通过抑制肿瘤血管生长从而达到治疗目的。结论：EGF-TCSredlk可以有效地抑制荷瘤小鼠实体瘤的生长,预示了该免疫毒素在肿瘤治疗中的潜在应用价值。

Antitumor Effect of Recombinant Immunotoxin EGF-TCSredlk on Tumor-bearing Mouse Model

Objective：To further observe the anti-tumor effect of recombinant toxin,we carried tumor inhibition test in vivo in naked mouse tumor model.Methods：The hepatoma cell BEL-7402 was inoculated subcutaneously on right armpit in naked mice and EGF-TCSredlk was injected intravenously（100,50,25 μg/kg） to mice for therapy after 6 days of inocluation.There was control group and mice were killed after 2 days of drug withdrawal,and the tumors were weighed and the tumor inhibitory rate was calculated;Tumor tissues were examined by immunohistochemistry.Result：The illustrated that EGF-TCSredlk could inhibit tumor growth markedly.The inhibition rate was75.5%、54.5%and 35.4% for high dosage group,middle dosage group and low dosage group respectively.Variance analysis illustrated that EGF-TCSredlk could markedly inhibit the growth of naked mouse tumors,variance analysis had significant difference（Welch=82.617,P=0.000）;Immunohistochemistry experiment showed that EGF-TCSredlk could makedly inhibit tumor angiogenesis.There were no visible blood vessels in tumor tissues in high dosage group and there were fewer blood vessels in tumor tissues in middle and low dosage group than those in control group,which revealed that perhaps EGF-TCSredlk inhibited tumor growth and migration by inhibiting tumor angiogenesis.Conclusions：EGF-TCSredlk can inhibit the growth of solid tumors in tumor-bearing mice and the priliminary results suggested the potential applications of this preparation in cancer therapy.